Jump to content

RH-34

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Ffffrr (talk | contribs) at 22:41, 5 March 2022 (Importing Wikidata short description: "Chemical compound" (Shortdesc helper)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

RH-34
Clinical data
Routes of
administration
?
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
  • 3-[2-(2-methoxybenzylamino)ethyl]-1H-quinazoline-2,4-dione
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H19N3O3
Molar mass325.368 g·mol−1
3D model (JSmol)
  • O=c1[nH]c2ccccc2c(=O)n1CCNCc3ccccc3OC
  • InChI=1S/C18H19N3O3/c1-24-16-9-5-2-6-13(16)12-19-10-11-21-17(22)14-7-3-4-8-15(14)20-18(21)23/h2-9,19H,10-12H2,1H3,(H,20,23) ☒N
  • Key:NUAJBITWGGTZCM-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

RH-34 is a compound which acts as a potent and selective partial agonist for the 5-HT2A serotonin receptor subtype. It was derived by structural modification of the selective 5-HT2A antagonist ketanserin, with the 4-(p-fluorobenzoyl)piperidine moiety replaced by the N-(2-methoxybenzyl) pharmacophore found in such potent 5-HT2A agonists as NBOMe-2C-B and NBOMe-2C-I. This alteration was found to retain 5-HT2A affinity and selectivity, but reversed activity from an antagonist to a moderate efficacy partial agonist.[1][2][3]

RH-34 is a controlled substance in Hungary[4] and Brazil.[5]

See also

References

  1. ^ Ralf Heim. Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts. (German)
  2. ^ Maria Silva. Theoretical study of the interaction of agonists with the 5-HT2A receptor. Universität Regensburg, 2009.
  3. ^ Silva ME, Heim R, Strasser A, Elz S, Dove S (January 2011). "Theoretical studies on the interaction of partial agonists with the 5-HT(2A) receptor". Journal of Computer-aided Molecular Design. 25 (1): 51–66. Bibcode:2011JCAMD..25...51S. CiteSeerX 10.1.1.688.2670. doi:10.1007/s10822-010-9400-2. PMID 21088982. S2CID 3103050.
  4. ^ A Magyarországon megjelent, a Kábítószer és Kábítószer-függőség Európai Megfigyelő Központjának Korai Jelzőrendszerébe (EMCDDA EWS) 2005 óta bejelentett ellenőrzött anyagok büntetőjogi vonatkozású besorolása
  5. ^ Anvisa